Project 2: Human Melanoma -- Etiology, Progression, and Therapy

Investigator: Boris C. Bastian, MD, PhD
Sponsor: Wistar Institute

Location(s): United States


Project 2: The KIT signaling pathway as a therapeutic target in melanoma
Project Leader: Boris Bastian, M.D.
Specific Aims:
Aim 1: Characterize genetic alterations of the KIT pathway in patient samples.
Aim 2: Determine the functional role of genetic alterations in the KIT pathway in melanoma.
Aim 3: Determine predictive factors of therapy response and resistance in melanoma patients treated with KIT inhibitors.